Can Blood Thinners Cause Low Hemoglobin?

Blood thinners can lower your hemoglobin, and the most common reason is bleeding you may or may not notice. Anticoagulants like warfarin and the newer direct oral anticoagulants, as well as antiplatelet drugs like aspirin, all increase the risk of blood loss from the gut, urinary tract, and other sites. That lost blood carries hemoglobin with it, and if the losses outpace your body’s ability to make new red blood cells, your hemoglobin drops. The relationship is well-documented but more layered than a simple cause-and-effect story, because the bleeding that blood thinners provoke sometimes reveals problems that were already there.

How Blood Thinners Lead to Lower Hemoglobin

Blood thinners do not destroy hemoglobin or prevent your bone marrow from producing it. They lower hemoglobin indirectly, by making you bleed more easily and more persistently. Even minor sources of blood loss that your body would normally seal off quickly can become slow, steady leaks when clotting is impaired. A small erosion in the stomach lining, a polyp in the colon, or a patch of fragile blood vessels in the intestine might ooze just enough blood each day to gradually deplete your iron stores and pull your hemoglobin down over weeks or months.

In surgical settings, this effect is measurable and consistent. A study of patients undergoing hip fracture repair found that those on anticoagulant or antiplatelet drugs experienced significantly greater drops in hemoglobin than patients not taking these medications, even after adjusting for fracture severity and operative time.¹ That finding mirrors what doctors see in the outpatient world: people on blood thinners tend to drift toward lower hemoglobin levels over time, and the drift accelerates when there is any source of bleeding, however small.

Low-Dose Aspirin and a Slow Hemoglobin Decline

Aspirin is not usually grouped with “serious” blood thinners in most people’s minds, but it has a surprisingly consistent effect on hemoglobin. The ASPREE trial, a large randomized study involving over 19,000 older adults, found that people assigned to daily low-dose aspirin developed anemia at a rate roughly 20 percent higher than those on placebo. Hemoglobin levels in the aspirin group declined more steeply over five years, and ferritin, the protein that reflects your body’s iron reserves, dropped faster too. At three years, about 13 percent of aspirin users had low ferritin compared with about 10 percent of non-users.²

What made this finding particularly striking was that it held up even after researchers accounted for major bleeding events. In other words, the hemoglobin decline was not driven only by dramatic episodes of blood loss. It appeared to stem from low-grade, chronic oozing in the gut, the kind that does not produce visible blood in your stool but quietly siphons off iron over months and years. Separate research on older adults taking daily low-dose aspirin confirmed an increased risk of iron-deficiency anemia, with aspirin users showing lower hemoglobin loads even when the difference did not always reach statistical significance in smaller samples.³

How Different Anticoagulants Compare

Warfarin has been the standard oral anticoagulant for decades, and the newer direct oral anticoagulants, often called DOACs, include drugs like dabigatran, rivaroxaban, apixaban, and edoxaban. When researchers have compared these two classes head-to-head for gastrointestinal bleeding, the overall picture is roughly a draw. A meta-analysis of randomized controlled trials found that the risk of gastrointestinal bleeding with DOACs as a group was similar to warfarin.⁴ A separate nationwide cohort study also found no significant difference in the average hemoglobin drop during gastrointestinal bleeding episodes between warfarin and DOAC users.⁵

Within the DOAC class, though, there are differences worth knowing about. Rivaroxaban stood out in the meta-analysis as carrying a higher gastrointestinal bleeding risk than warfarin, with about a 38 percent increase. Edoxaban trended in the opposite direction, with fewer bleeding events than warfarin, though that finding did not quite reach statistical significance.⁴ If you are on rivaroxaban and your hemoglobin has been creeping downward, the choice of anticoagulant itself may be part of the explanation, and switching to a different DOAC is sometimes a conversation worth having with your doctor.

Heavy Periods on Anticoagulants

For women who are still menstruating, blood thinners create a problem that is often underappreciated in clinical practice. About 70 percent of menstruating women on oral anticoagulants experience heavy menstrual bleeding, and the consequences go beyond inconvenience. Heavy periods on these medications can lead to iron deficiency, with or without outright anemia, and contribute to fatigue, reduced quality of life, and missed days at work or school.⁶ This is a major and underreported route through which blood thinners lower hemoglobin, and it deserves a direct conversation with a prescriber rather than silent endurance. Options for managing the problem exist, including hormonal treatments that can reduce menstrual flow without necessarily stopping anticoagulation.

Drug Combinations That Make Bleeding Worse

One of the fastest ways to turn moderate bleeding risk into a serious problem is to combine blood thinners with other drugs that also affect clotting or irritate the gut lining. The combination of an oral anticoagulant with a nonsteroidal anti-inflammatory drug like ibuprofen or naproxen roughly doubles the rate of major bleeding. In patients being treated for blood clots, concurrent NSAID use was associated with a major bleeding rate more than three times higher than periods without NSAID use.⁷ The combination of an oral anticoagulant with aspirin is similarly hazardous. One study reported a 13-fold increase in the risk of upper gastrointestinal bleeding when patients used both, and among those who did bleed, many required transfusions.⁸

Herbal and dietary supplements add another underappreciated layer. A systematic review found that 78 different herbs, foods, or dietary supplements had been reported to interact with warfarin. More than half of them potentiated the drug, meaning they made its blood-thinning effect stronger. Twenty unique herbs and supplements were linked to bleeding events ranging from gum bleeding to fatal intracranial hemorrhage.⁹ If you are on warfarin and taking fish oil, ginkgo, garlic supplements, or similar products, your effective anticoagulation level may be higher than your doctor assumes, and your hemoglobin may be paying the price.

When Falling Hemoglobin Reveals Something Else

Here is the part of this story that catches many patients off guard: blood thinners do not always cause the bleeding that lowers your hemoglobin. Sometimes they merely unmask bleeding from a pre-existing problem that would have stayed invisible without anticoagulation. This distinction matters enormously because it changes what should happen next.

A classic study found that in patients on anticoagulants who developed occult gastrointestinal bleeding, 15 out of 16 who underwent a diagnostic workup had previously undiagnosed lesions in their intestinal tract. The investigators concluded that bleeding in a patient on an anticoagulant should not simply be blamed on the drug; it frequently signals underlying disease that needs its own evaluation.¹⁰ A more recent study of patients on warfarin who were screened for anemia reinforced this point. Among those who were found to be anemic, gastrointestinal malignancies were discovered in 11 patients, pre-cancerous lesions in 14 others, and additional bleeding lesions like ulcers or abnormal blood vessels in 30 percent more.¹¹

Data from the large RE-LY trial, which compared dabigatran to warfarin, showed that about 8 percent of major gastrointestinal bleeding episodes were caused by previously undiagnosed cancers of the GI tract. That rate was similar regardless of which blood thinner patients were taking. Most of the cancer-related bleeding presented as chronic, slow blood loss rather than a dramatic acute event, and about a third of cases were entirely occult, detected only by a drop in hemoglobin or a positive stool test rather than by visible blood.¹² The practical takeaway is clear: if your hemoglobin drops while you are on a blood thinner, do not assume the drug alone explains it. A workup to look for an underlying source is warranted, and the urgency increases if the drop is progressive or unexplained by any obvious bleeding.

Who Faces the Highest Risk

Age is the single most consistent risk amplifier. In a retrospective analysis of anticoagulated patients, those over 65 had nearly three times the odds of experiencing a bleeding event compared to younger patients, regardless of how severe their anemia was at baseline.¹³ Anemia itself is common in older adults, affecting roughly a quarter of people over 70, and it independently predicts hemorrhage in patients on anticoagulants. One large dataset found that anemia was associated with a more than fourfold increase in the risk of hemorrhage among anticoagulated patients with atrial fibrillation.¹⁴ This creates a vicious cycle: blood thinners lower hemoglobin, and lower hemoglobin amplifies the risk of further bleeding.

Kidney disease compounds the problem from multiple directions. Patients with advanced chronic kidney disease are already prone to anemia because their kidneys produce less erythropoietin, the hormone that stimulates red blood cell production. On top of that, the uremia associated with kidney failure impairs platelet function, increasing bleeding tendency independently of any anticoagulant. Studies have found that the higher bleeding risk in patients with severe kidney disease is not primarily about which anticoagulant they take but about these baseline vulnerabilities.¹⁵ If your kidneys are already struggling, your hemoglobin starts lower and drops faster on blood thinners.

Patients who already have anemia when they begin anticoagulation face a particularly steep risk gradient. Research on anticoagulated patients with baseline anemia found they had roughly double the risk of significant bleeding and triple the risk of fatal bleeding compared to non-anemic patients.¹³ This is a strong argument for checking and, where possible, correcting anemia before or alongside anticoagulation rather than ignoring it as a background issue.

Monitoring Your Hemoglobin on Blood Thinners

Given everything above, regular blood count monitoring makes sense for anyone on long-term anticoagulation. Some anticoagulation clinics order a complete blood count at baseline, again at three months, and then yearly as a standing practice.¹⁶ Serial blood counts can catch a quietly falling hemoglobin before it becomes symptomatic, flag abnormal platelet counts, and prompt earlier investigation of hidden bleeding sources.¹⁷ The challenge is that no universally agreed-upon schedule exists yet, and many primary care providers do not routinely recheck blood counts once a patient is stable on anticoagulation. If your doctor has not checked your hemoglobin recently and you have been on a blood thinner for a while, it is reasonable to ask for a blood count.

Symptoms to watch for include progressive fatigue, shortness of breath on exertion you used to handle comfortably, pale skin, dizziness, and a faster-than-usual heartbeat. These are all signs that your hemoglobin may have drifted into a range where your tissues are not getting enough oxygen. Dark or tarry stools, blood in the urine, or unusually heavy bruising warrant more urgent attention.

What Happens When Bleeding Is Found

If your hemoglobin drops and your doctor suspects gastrointestinal bleeding, an endoscopy, looking into the upper or lower GI tract with a camera, is often the next step. In patients on warfarin whose blood-thinning levels were well above the therapeutic range, most presented with dark stools or simply with symptomatic anemia. Active bleeding was found in only about 18 percent of those who underwent upper endoscopy or colonoscopy, and endoscopic intervention was needed in about a quarter of cases.¹⁸ Patients who were also taking antiplatelet drugs had more than double the odds of having a findable bleeding source, reinforcing the danger of combining these medications.

When no active bleeding source is visible, the workup can feel frustrating, but the investigation itself still has value. Small-bowel capsule endoscopy, where you swallow a camera pill, can visualize parts of the intestine that standard scopes do not reach. Iron studies help clarify whether the anemia is from chronic blood loss, poor iron absorption, or something else entirely. In some cases, treating the anemia with iron supplementation while continuing anticoagulation is the most practical path forward, with ongoing monitoring to make sure hemoglobin stabilizes.

Genetic Variation in Bleeding Risk

Not everyone on the same blood thinner at the same dose faces the same risk of hemoglobin loss, and genetics is one reason why. For dabigatran, a genome-wide analysis of participants in the RE-LY trial identified a variant in the CES1 gene that influenced how much of the drug remained in the bloodstream. Each copy of the minor allele lowered trough drug levels by about 15 percent and reduced the risk of any bleeding by roughly a third.¹⁹ For warfarin, variants in genes like CYP2C9 and VKORC1 are already well known for influencing dose requirements, but a separate variant in CYP4F2 was associated with a 38 percent lower risk of major bleeding in the largest community-based study on the topic.²⁰

Pharmacogenomic testing before starting warfarin has been available for years, though its uptake in clinical practice remains uneven. For DOACs, genetic testing is still mostly a research tool. The practical reality is that your doctor adjusts dosing based on kidney function, body weight, age, and how your blood counts respond over time. But these genetic findings do explain why two patients on identical regimens can have very different hemoglobin trajectories, and they hint at a future where prescribing can be more precisely tailored.

The Feedback Loop Between Anemia and Anticoagulation

One of the more insidious aspects of this relationship is that anemia and anticoagulation can feed off each other. As described earlier, anemia itself is an independent predictor of bleeding in anticoagulated patients. Research in patients with atrial fibrillation has highlighted that anemia and iron deficiency worsen several AF-related problems, including exercise intolerance, heart failure symptoms, and overall functional decline.²¹ A patient whose hemoglobin drops from anticoagulation-related bleeding may become more sedentary, develop worsening heart failure symptoms, and then be at still higher risk for further bleeding complications.

Breaking this cycle typically requires treating the anemia directly rather than simply watching and waiting. That can mean oral or intravenous iron, adjusting the anticoagulant dose or switching to a drug with a lower bleeding profile, addressing any correctable bleeding source, and rechecking blood counts more frequently until hemoglobin stabilizes. The evidence is clear that ignoring a low hemoglobin in someone on blood thinners is not a neutral choice. It raises future bleeding risk and worsens the very conditions that made anticoagulation necessary in the first place.